Statements (47)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
drug
|
| gptkbp:activeDuring |
nitric oxide
|
| gptkbp:clinicalTrials |
Phase 3
intensive care units short-term treatment increased survival rates NO-CLD study NO-ELD study decreased need for ECMO improved oxygenation neonatal units reduced pulmonary artery pressure NINOS_study |
| gptkbp:contraindication |
dizziness
respiratory distress tachycardia pulmonary edema concurrent use with certain medications |
| gptkbp:date |
FDA_approved
|
| gptkbp:dosageForm |
inhalation gas
|
| gptkbp:formulation |
gas
|
| gptkbp:hasPopulation |
adults
newborns |
| https://www.w3.org/2000/01/rdf-schema#label |
Inomax
|
| gptkbp:mandates |
neonatal hypoxia
|
| gptkbp:manufacturer |
gptkb:Ikaria
|
| gptkbp:marketedAs |
gptkb:Canada
gptkb:European_Union gptkb:United_States |
| gptkbp:packaging |
cylinder
|
| gptkbp:patentStatus |
patented
generic available |
| gptkbp:provides |
gptkb:American_Heart_Association
gptkb:European_Society_of_Cardiology gptkb:American_Academy_of_Pediatrics |
| gptkbp:researchAreas |
neonatology
critical care medicine pulmonary_medicine |
| gptkbp:route |
inhalation
|
| gptkbp:shelfLife |
12 months
|
| gptkbp:sideEffect |
headache
nausea hypotension methemoglobinemia |
| gptkbp:storage |
room temperature
|
| gptkbp:triggerType |
vasodilation
|
| gptkbp:usedFor |
treatment of pulmonary hypertension
|